Venetoclax-Rituximab in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Copur, Mehmet S. [1 ]
Gauchan, Dron [1 ]
Crockett, David [1 ]
机构：
[1] Catholic Hlth Initiat, St Francis Canc Treatment Ctr, Grand Isl, NE 68803 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 22期
关键词：
CHLORAMBUCIL; TRIALS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2142 / +
页数：2
相关论文
共 50 条
  • [31] Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (03) : 178 - 183
  • [32] Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia
    Dibb, James T.
    Long, Nicola
    Eide, Christopher A.
    Kurtz, Stephen E.
    Tognon, Cristina E.
    Tyner, Jeffrey W.
    Druker, Brian J.
    BLOOD, 2020, 136
  • [33] Mechanisms of Venetoclax Resistance in Chronic Lymphocytic Leukemia
    Frenzel, Lukas P.
    Herling, Carmen D.
    Abedpour, Nima
    Weiss, Jonathan
    Mayer, Petra
    Cartolano, Maria
    Berg, Valeska
    Kutsch, Nadine
    Cramer, Paula
    Wendtner, Clemens-Martin
    Persigehl, Thorsten
    Saleh, Andreas
    Altmueller, Janine
    Nurnberg, Peter
    Pallasch, Christian
    Achter, Viktor
    Lang, Ulrich
    Eichhorst, Barbara F.
    Castiglione, Roberta
    Schaefer, Stephan C.
    Buettner, Reinhard
    Kreuzer, Karl-Anton
    Reinhardt, Hans Christian
    Hallek, Michael J.
    Peifer, Martin
    BLOOD, 2017, 130
  • [34] An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Salvaris, Ross
    Opat, Stephen
    FUTURE ONCOLOGY, 2020, 17 (04) : 371 - 387
  • [35] Time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): first presentation of 4-year data from the MURANO study
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara
    Hillmen, Peter
    D'Rozario, James
    Assouline, Sarit
    Owen, Carolyn
    Robak, Tadeusz
    de la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Lamanna, Nicole
    Kim, Su Young
    Wu, Jenny
    Jiang Yanwen
    Wang, Jue
    Lefebure, Marcus
    Boyer, Michelle
    Humphrey, Kathryn
    Kater, Arnon
    LEUKEMIA & LYMPHOMA, 2020, 61 : 268 - 270
  • [36] Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Herling, Carmen Diana
    Holtick, Udo
    Scheid, Christoph
    Cramer, Paula
    Sasse, Stephanie
    von Tresckow, Bastian
    Tuchscherer, Armin
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Frenzel, Lukas P.
    HAEMATOLOGICA, 2019, 104 (05) : E224 - E226
  • [37] Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Seymour, John F.
    Kipps, Thomas J.
    Eichhorst, Barbara F.
    Hillmen, Peter
    D'Rozario, James
    Assouline, Sarit
    Owen, Carolyn
    Robak, Tadeusz
    de la Serna, Javier
    Jaeger, Ulrich
    Cartron, Guillaume
    Montillo, Marco
    Lamanna, Nicole
    Kim, Su Young
    Wu, Jenny
    Jiang, Yanwen
    Wang, Jue
    Lefebure, Marcus
    Boyer, Michelle
    Humphrey, Kathryn
    Kater, Arnon P.
    BLOOD, 2019, 134
  • [38] The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
    Schieber, Michael
    Ma, Shuo
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 9 - 17
  • [39] Treatment of relapsed chronic lymphocytic leukemia after venetoclax
    Thompson, Meghan C.
    Mato, Anthony R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 18 - 23
  • [40] Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia
    Stephens, Deborah M.
    BLOOD, 2019, 134 (20) : 1691 - 1696
12345